Europska Unija - danski - EMA (European Medicines Agency)

sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - midler til dermatitis, undtagen kortikosteroider - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.

Danska - danski - Lægemiddelstyrelsen (Danish Medicines Agency)

haleon denmark aps - caffein, paracetamol - filmovertrukne tabletter - 500+65 mg

Danska - danski - Lægemiddelstyrelsen (Danish Medicines Agency)

2care4 aps - duloxetinhydrochlorid - enterokapsler, hårde - 60 mg

Europska Unija - danski - EMA (European Medicines Agency)

amivas ireland ltd - artesunate - malaria - antiprotozomidler - artesunate amivas is indicated for the initial treatment of severe malaria in adults and children. det bør overvejes at officielle vejledning om hensigtsmæssig brug af malaria agenter.

Europska Unija - danski - EMA (European Medicines Agency)

sanofi b.v. - avalglucosidase alfa - glycogen opbevaring sygdom type ii - andre alimentary tract and metabolism produkter, - nexviadyme (avalglucosidase alfa) is indicated for long-term enzyme replacement therapy for the treatment of patients with pompe disease (acid α-glucosidase deficiency).

Europska Unija - danski - EMA (European Medicines Agency)

sanofi b.v. - olipudase alfa - acid sphingomyelinase deficiency (asmd) type a/b or type b - andre alimentary tract and metabolism produkter, - xenpozyme is indicated as an enzyme replacement therapy for the treatment of non-central nervous system (cns) manifestations of acid sphingomyelinase deficiency (asmd) in paediatric and adult patients with type a/b or type b.

Europska Unija - danski - EMA (European Medicines Agency)

pharmaxis europe limited - mannitol - cystisk fibrose - hoste og kolde præparater - bronchitol er indiceret til behandling af cystisk fibrose (cf) hos voksne i alderen 18 år og derover som tillægsbehandling til den bedste plejestandard.

Europska Unija - danski - EMA (European Medicines Agency)

eli lilly nederland b.v. - duloxetin - anxiety disorders; diabetic neuropathies; depressive disorder, major - psychoanaleptics, - behandling af alvorlig depressiv lidelse. behandling af diabetisk perifer neuropatisk smerte. behandling af generaliseret angst. cymbalta er indiceret hos voksne.

Europska Unija - danski - EMA (European Medicines Agency)

otsuka novel products gmbh - delamanid - tuberkulose, multidrugt-resistent - antimyco-bakterielle midler - deltyba is indicated for use as part of an appropriate combination regimen for pulmonary multi-drug resistant tuberculosis (mdr-tb) in adults, adolescents, children and infants with a body weight of at least 10 kg when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability (see sections 4. 2, 4. 4 og 5. det bør overvejes at officielle vejledning om hensigtsmæssig brug af antibakterielle midler..

Europska Unija - danski - EMA (European Medicines Agency)

eli lilly nederland b.v. - duloxetin - neuralgia; diabetic neuropathies; depressive disorder, major - psychoanaleptics, - duloxetin, lilly, er angivet i voksne til:behandling af depressiv disordertreatment af diabetisk perifer neuropatisk paintreatment af generaliseret angst disorderduloxetine lilly er indiceret hos voksne.